ClinicalTrialsFinder

Resectable HER2-positive Breast Cancer Clinical Trials in Shanghai, Shanghai Municipality

1 recruitingShanghai, Shanghai Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 3

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Resectable HER2-positive Breast Cancer
Shanghai JMT-Bio Inc.1,800 enrolled1 locationNCT07441460